NACSELD acute-on-chronic liver failure (NACSELD-ACLF) score predicts 30-day survival in hospitalized patients with cirrhosis.

Jacqueline G O'LearyK Rajender ReddyGuadalupe Garcia-TsaoScott W BigginsFlorence WongMichael B FallonRam M SubramanianPatrick S KamathPaul ThuluvathHugo E VargasBenedict MaliakkalPuneeta TandonJennifer LaiLeroy R ThackerJasmohan Singh Bajaj

Published in: Hepatology (Baltimore, Md.) (2018)

Although infection status remains an important predictor of death, NACSELD-ACLF was independently validated in a separate large multinational prospective cohort as a simple, reliable bedside tool to predict 30-day survival in both infected and uninfected patients hospitalized with a diagnosis of cirrhosis. (Hepatology 2018;67:2367-2374).

Keyphrases

liver failure
hepatitis b virus
end stage renal disease
newly diagnosed
ejection fraction
hiv infected
prognostic factors
drug induced
free survival
intensive care unit